Nefiracetam metabolism by human liver microsomes: role of cytochrome P450 3A4 and cytochrome P450 1A2 in 5-hydroxynefiracetam formation

被引:5
|
作者
Fujimaki, Y [1 ]
Arai, N [1 ]
Nakazawa, T [1 ]
Fujimaki, M [1 ]
机构
[1] Daiichi Pharmaceut Co Ltd, Drug Metab & Analyt Chem Res Lab, New Prod Res Labs 3, Edogawa Ku, Tokyo 1348630, Japan
关键词
D O I
10.1211/0022357011776144
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An in-vitro study was conducted to investigate the metabolism of nefiracetam in human liver microsomes and to identify the enzymes responsible for the metabolism. Nefiracetam was hydroxylated by human liver microsomes to 5-hydroxynefiracetam (5-OHN). Eadie-Hofstee plots for the formation of 5-OHN suggested substrate activation. The kinetic parameters, apparent K-m, V-max, and Hill coefficient, for the formation of 5-OHN by pooled human liver microsomes were 4012 muM, 2.66 nmol min(-1) (mg protein)(-1), and 1.65, respectively. The formation of 5-OHN was significantly correlated with cytochrome P450 (CYP)3A4-mediated testosterone 6 beta -hydroxylase activity and dextromethorphan N-demethylase activity. The 5-OHN formation was inhibited (94 %) by antibody to human CYP3A4/5. The 5-OHN formation was also inhibited by the CYP3A4 inhibitors ketoconazole and troleandomycin, but not significantly inhibited by several other P450 inhibitors. The microsomes containing cDNA-expressed CYP3A4 formed 5-OHN with sigmoidal kinetics. CYP3A5-containing microsomes did not form 5-OHN. These results indicated that CYP3A, most likely CYP3A4, was the major isozyme responsible for the formation of 5-OHN in human liver microsomes. CYP1A2 and CYP2C19 microsomes were also capable of forming 5-OHN. However, the contribution of CYP1A2 was considered to be relatively minor compared with that of CYP3A4, and the contribution of CYP2C19 was assumed to be negligible, based on the result of the immunoinhibition study and taking into account both the turnover rate by each isozyme and the relative abundance of each isozyme in human liver. We conclude that on average the formation of 5-OHN, the major metabolite of nefiracetam, is principally mediated by CYP3A4 with a relatively minor contribution by CYP1A2.
引用
收藏
页码:795 / 804
页数:10
相关论文
共 50 条
  • [21] Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes
    Zhu, MS
    Zhao, WP
    Jimenez, H
    Zhang, DL
    Yeola, S
    Dai, RK
    Vachharajani, N
    Mitroka, J
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (04) : 500 - 507
  • [22] Bacterial surface display of human cytochrome P450 1A2 and cytochrome P450 reductase for drug metabolite synthesis
    Quehl, Paul
    Hollender, Joel
    Jose, Joachim
    NEW BIOTECHNOLOGY, 2016, 33 : S26 - S26
  • [23] Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes
    Iribarne, C
    Picart, D
    Dreano, Y
    Bail, JP
    Berthou, F
    LIFE SCIENCES, 1997, 60 (22) : 1953 - 1964
  • [24] Molecular modeling of cytochrome P450 3A4
    Szklarz, GD
    Halpert, JR
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (03) : 265 - 272
  • [25] Sertraline and cytochrome P450 3A4 in dysthymia
    Dunn, E
    Helpard, B
    Steiner, M
    BIOLOGICAL PSYCHIATRY, 1997, 41 : 116 - 116
  • [26] Molecular modeling of cytochrome P450 3A4
    Grazyna D. Szklarz
    James R. Halpert
    Journal of Computer-Aided Molecular Design, 1997, 11 : 265 - 272
  • [27] Potential role for human cytochrome P450 3A4 in estradiol homeostasis
    Yu, AM
    Fukamachi, K
    Krausz, KW
    Cheung, C
    Gonzalez, FJ
    ENDOCRINOLOGY, 2005, 146 (07) : 2911 - 2919
  • [28] Molecular simulations of cytochrome P450 3A4
    Czapla, Luke
    Amaro, Rommie E.
    Kontoyianni, Maria
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [29] Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin
    Park, J. -E.
    Kim, K. -B.
    Bae, S. K.
    Moon, B. -S.
    Liu, K. -H.
    Shin, J. -G.
    XENOBIOTICA, 2008, 38 (09) : 1240 - 1251
  • [30] Biotransformation of zafirlukast by cytochrome P450 3A4
    Skordos, KW
    Yost, GS
    DRUG METABOLISM REVIEWS, 2003, 35 : 49 - 49